New drug cocktail aims to tackle Hard-to-Treat stomach and esophageal cancers
NCT ID NCT05187182
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This early-phase trial is testing a new targeted drug called CA-4948 combined with standard chemotherapy and immunotherapy for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery. The study will enroll 42 participants and will first find the safest dose of CA-4948, then test it in two groups: one with HER2-negative cancer and one with HER2-positive cancer (adding trastuzumab). The main goals are to check safety and find the right dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CA-4948 (a targeted drug) combined with chemotherapy (FOLFOX), immunotherapy (nivolumab or pembrolizumab), and possibly trastuzumab
What this could lead to
If successful, this could point toward a new combination treatment for advanced stomach and esophageal cancers that are hard to treat.
What could go wrong
This is an early Phase I trial with only 42 people, so safety and dosing are still being figured out. The combination may cause significant side effects or not work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.